Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.3 (
collagenase
)
18,340
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently, we reported our findings regarding the elevated secretion patterns of proinflammatory cytokines obtained from peripheral blood monocytes of hypertensive patients. To investigate the direct impact of these preactivated monocytes, the adhesion of monocytes from normal controls and hypertensive patients to vascular endothelial cell monolayers was determined spontaneously and after in vitro stimulation with either lipopolysaccharide (LPS) or angiotensin II (
Ang II
), with or without preincubation with the AT1 receptor antagonist eprosartan. Peripheral blood monocytes from 20 patients and 20 healthy individuals were isolated by density gradient centrifugation and plastic adherence; endothelial cells were obtained from human umbilical cords by
collagenase
digestion. The adhesion was determined by an assay with 51Cr-radiolabeled monocytes. Oxygen species release induced by phorbol myristate acetate (PMA) as a further activation marker was analyzed for monocytes and HUVEC by chemiluminescence (CL). Spontaneous adhesion of monocytes from patients and the adhesion after stimulation with
Ang II
were significantly increased compared with normal controls (P<0.05). Preincubation with eprosartan diminished the adhesion in both groups to comparable levels. In monocytes, peak levels of PMA and
Ang II
induced CL analysis were significantly higher in patients (P<0.005). These data indicate that preactivated monocytes from hypertensives may be of pathogenic importance in atherosclerosis.
...
PMID:Preactivated monocytes from hypertensive patients as a factor for atherosclerosis? 1142 15
Angiotensin II
(
Ang II
)-mediated stimulation of fibroblast growth and collagen type I synthesis is believed to be an important component of the cardiac remodeling process in hypertension and chronic ischemia.
Ang II
-mediated oxidative stress could be important in enhanced fibroblast growth and collagen formation. Accordingly, we postulated that the PPAR-gamma ligand, pioglitazone, which is known to modulate oxidative stress, would alter
Ang II
-induced formation of collagen type I in cardiac fibroblasts. Cardiac fibroblasts were treated with different concentrations (10(-8) to 10(-6) M) of
Ang II
for different times (6 hours, 12 hours, and 24 hours).
Ang II
increased the expression of collagen type I in a concentration- and time-dependent fashion (P<0.01 versus control).
Ang II
also decreased the expression and activity of matrix metalloproteinase (MMP)-1 (
MMP-1
, P<0.05 versus control). These effects of
Ang II
were attenuated by pretreatment of cells with pioglitazone (10 micromol/L).
Ang II
stimulated the intracellular generation of reactive oxygen species (ROS), and this effect was also attenuated by pioglitazone.
Ang II
treatment activated the redox-sensitive transcription factor NF-kappaB, and pioglitazone pretreatment blocked this effect of
Ang II
.
Ang II
also activated another transcription factor, AP-1, but this effect of
Ang II
was not modulated by pioglitazone. In other experiments, we observed that trolox, the water soluble analog of vitamin E, attenuated the effects of
Ang II
on the expression of collagen type I and
MMP-1
, in a manner similar to pioglitazone. Thus, pioglitazone attenuates
Ang II
-mediated collagen type I synthesis in cardiac fibroblasts. The effects of pioglitazone are mediated by the modulation of ROS release and redox-sensitive transcription factor NF-kappaB.
...
PMID:Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. 1538 78
Angiotensin II
(
Ang II
) is a powerful mediator of adverse cardiac remodeling and fibrosis. However, the mechanisms of
Ang II
-induced myocardial fibrosis remain to be clarified. We postulated that
Ang II
alters transforming growth factor beta (TGF-beta) receptor expression, specifically that of endoglin, and thereby modulates cardiac fibroblast (CF) collagen metabolism. Experiments were conducted using CF from adult Sprague Dawley rats to determine the expression of TGF-beta1 receptors including endoglin, and the role of
Ang II
type 1 (AT1) and type 2 (AT2) receptors, and MAPK p42/44 in this process. The functional role of endoglin in modulating
Ang II
effects on
matrix metalloproteinase-1
(
MMP-1
) and type I collagen expression was also analyzed. Endoglin gene and protein expression were consistently identified in quiescent CFs.
Ang II
increased the expression of endoglin mRNA and protein in a concentration and time-dependent manner, with no effect on TGF-beta receptors I and II expression. This effect was AT1 receptor mediated, because AT1 receptor antagonists valsartan, candesartan, and losartan inhibited
Ang II
-induced endoglin expression, whereas the AT2 receptor antagonist PD123319 had no effect. MAPKp42/44 inhibition attenuated
Ang II
-induced endoglin expression.
Ang II
-induced decrease in
MMP-1
protein expression and increase in type I collagen protein expression were both blocked by a specific endoglin antibody. Hence, our results indicate that endoglin is upregulated in CFs by
Ang II
via the AT1 receptor and modulates profibrotic effects of
Ang II
. These findings provide novel insights into
Ang II
-induced cardiac remodeling.
...
PMID:Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. 1553 34
Angiotensin II
(
Ang II
)-mediated hypertension increases the risk for acute coronary syndrome, a consequence of atherosclerotic plaque rupture, which may be caused by matrix metalloproteinases (MMPs). Here, we show that human primary monocytes stimulated with tumor necrosis factor alpha (TNF-alpha) and granulocyte macrophage-colony stimulating factor (GM-CSF) release
Ang II
, which is an integral component of the signal transduction pathway that leads to
MMP-1
production. An
Ang II
-mediated increase in
MMP-1
synthesis occurred only in conjunction with cytokine stimulation. Moreover,
Ang II
mediated its effect through the
Ang II
type 2 (AT(2)) receptor, as demonstrated by enhancement of
MMP-1
production by an AT(2) agonist, CGP-42112A, and inhibition of
MMP-1
production by PD1233319, an AT(2) antagonist. Additionally, exogenous
Ang II
caused a significant enhancement in
MMP-1
production by cytokine-stimulated monocytes, and the most effective enhancement occurrred when
Ang II
was added 6 h after stimulation. Furthermore,
Ang II
and the AT(2) agonist increased prostaglandin E(2) (PGE(2)), which in turn mediated the increase in
MMP-1
, as shown by the inhibition of
MMP-1
by indomethacin or aspirin. In contrast, the AT(2) antagonist inhibited the PGE(2) production induced by TNF-alpha and GM-CSF.
Ang II
, through its interaction with the AT(2) receptor, has a central role in mediating the PGE(2)-dependent production of
MMP-1
by monocytes stimulated with TNF-alpha and GM-CSF. These observations provide insight into the association between hypertension and acute coronary syndrome and a possible mechanism by which Ang-converting enzyme inhibitor and aspirin may reduce the risk for heart attacks.
...
PMID:Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. 1581 99
Glomerulosclerosis, interstitial fibrosis, and tubular atrophy occur with end-stage kidney failure, irrespective of the primary etiology. The transforming growth factor-beta (TGF-beta) is a key factor in these alterations either directly, by stimulating synthesis of extracellular matrix components and reducing
collagenase
production, or indirectly through other profibrogenic factors such as connective tissue growth factor (CTGF). TGF-beta is important for the proliferation of intrarenal fibroblasts and the epithelial-mesenchymal transition through which tubular cells become fibroblasts. Although several factors induce TGF-beta expression in the kidney, one very interesting aspect is the link between the renin-angiotensin-aldosterone (Aldo) system (RAAS) and TGF-beta.
Angiotensin II
(ANG II) stimulates TGF-beta expression in the kidney by various mechanisms and upregulates receptors for TGF-beta. ANG II can directly phosphorylate Smads without inducing TGF-beta. Recent data provide compelling evidence that other components of the RAAS including ANG III, renin, and Aldo also activate the TGF-beta system. As direct modulation of the TGF-beta system is not yet feasible in humans, angiotensin-converting enzyme (ACE) inhibitors and angiotensin type 1 (AT1)-receptor blockers are currently the most potential drugs to interfere with this ANG II-mediated TGF-beta expression. This review highlights some current aspects of the interaction between the RAAS and the TGF-beta axis.
...
PMID:Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. 1698 15
Angiotensin II
exerts its central nervous system effects primarily via its receptors AT1 and AT2, and it participates in the pathogenesis of ischemia via AT1. The selective AT1 receptor blocker (ARB) is used in the hypertension treatment, and it exerts a variety of pleiotropic effects, including antioxidative, antiapoptotic, and anti-inflammatory effects. In this study, we investigated the therapeutic effect of the ARB telmisartan in experimental intracerebral hemorrhage (ICH) in normotensive rats. ICH was induced via the
collagenase
infusion or autologous blood injection. Either telmisartan at 30 mg/kg/dose or phosphate-buffered saline was orally administered 2 h after ICH induction. We evaluated hemorrhage volume, brain water content, and functional recovery, and we performed the histological analysis for terminal deoxynucleotidyl transferase dUTP nick-end labeling, leukocyte infiltration, and microglia activation. A variety of intracellular signals, in terms of oxidative stress, apoptotic molecules, and inflammatory mediators, were also measured. Telmisartan reduced hemorrhage volume, brain edema, and inflammatory or apoptotic cells in the perihematomal area. Telmisartan was noted to induce the expression of endothelial nitric-oxide synthase and peroxisome proliferator-activated receptor gamma and decrease oxidative stress, apoptotic signal, tumor necrosis factor-alpha, and cyclooxygenase-2 expression. The telmisartan-treated rats exhibited less pronounced neurological deficits and recovered better. Thus, telmisartan seems to offer neural protection, including antiapoptosis, anti-inflammatory, and antioxidant benefits in the intracerebral hemorrhage rat model.
...
PMID:Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. 1753 8
The present study was designed to assess the effect of matrine, an active component of Chinese traditional medicine, on angiotensin II (
Ang II
)-induced hyperplastic growth of cardiac fibroblasts in vitro. Cardiac fibroblasts were prepared from hearts of neonatal Kunming mice by
collagenase
disruption. Cultured cardiac fibroblasts were either not treated, treated with 0.1 microM
Ang II
, or matrine (2.0 approximately 4.0 mM) plus
Ang II
for 12-72 hr. Cell morphology was monitored under an inverted phase contrast microscope. Number of cells was counted with a haemocytometer. Cell apoptosis was determined by propidium iodide/Hoechst 33342 staining and flow cytometry. The cleaved caspase-3 fragment expression, anti-apoptotic Bcl-2 and pro-apoptotic Bax protein expressions were also studied. The results show that
Ang II
stimulation resulted in hyperplastic growth of cardiac fibroblasts. Matrine significantly, dose and time dependently inhibited
Ang II
-induced cell proliferation. Matrine addition to the culture medium led to most cells being arrested in the G1 phase of the cell cycle, the fraction of cells in S phase was markedly decreased compared to control and
Ang II
alone groups. Cell apoptosis in matrine treatment group was markedly increased, accompanied by down-regulation in Bcl-2/Bax ratio and up-regulation in cleaved caspase-3 activity. These results suggest that matrine can induce apoptosis and thereby inhibit
Ang II
-induced hyperplasic growth of cardiac fibroblasts. The regulations of matrine on Bcl-2/Bax expression and caspase-3 activation may be the pro-apoptotic mechanisms involved.
...
PMID:Matrine induces apoptosis in angiotensin II-stimulated hyperplasia of cardiac fibroblasts: effects on Bcl-2/Bax expression and caspase-3 activation. 1757 9
Left ventricular dysfunction is associated with reperfusion injury occurring during open-heart surgery. There is an increased secretion of angiotensin II (
Ang II
) and increased matrix metalloproteinases (MMPs) activities associated with open-heart surgery that may affect the cardiac extracellular matrix (ECM). The goal of this study was to determine the effects of
Ang II
and selective angiotensin II receptor (AT1-R and AT2-R) blockers on the enzymatic activities of MMPs in primary adult murine cardiac fibroblasts (CF). Our hypothesis is that Aug II, with and without a selective receptor blocker, differentially affects CF MMPs activities. The CF were treated with
Ang II
(10(-6) M) and doses of AT1-R and AT2-R blockers (losartan and PD123319, respectively) at doses of 10(-7) to 10(-5) M for 48 hours. The
Ang II
-stimulated CF reduced
collagenase
activities by only 24% (p = 0.004); however, the MMP-2 and MMP-9 gelatinase activities were reduced by 42% and 39%, respectively (p = 0.022). The losartan dose dependently increased MMP-2 (p = 0.02) and MMP-9 (ns). PD123319 at 10(-5) M significantly reduced MMP-2 and MMP-9 activities compared with the
Ang II
group (p = 0.014 and p = 0.02, respectively). The doses of PD123319 at 10(-6) and 10(-7) M increased the MMP-2 and MMP-9 enzymatic activities significantly above the
Ang II
only group. Thus,
Ang II
and AT1-R and AT2-R differentially affect the
collagenase
and gelatinase MMPs activities released by cardiac fibroblasts.
...
PMID:Effect of angiotensin II on primary cardiac fibroblast matrix metalloproteinase activities. 1763 35
Angiotensin II
(
Ang II
) is a critical effector in the renin-angiotensin system (RAS), which modulates cardiovascular homeostasis, and the matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) related metabolism of extracellular matrix (ECM). Angiotensin(1-7) [Ang(1-7)] is another bioactive peptide in the RAS and is considered to have opposite effects to
Ang II
. However, the modulation of MMPs and TIMPs by Ang(1-7) is largely unclear in cardiocytes, and the antagonistic effects of Ang(1-7) on
Ang II
-mediated expression of MMPs and TIMPs have yet to be identified. In the present study, we examined the transcript expression of MMPs and TIMPs in human cardiac fibroblasts (HCF) and myocytes (HCM) after
Ang II
or Ang(1-7) stimulation, and analysed the antagonistic effects of Ang(1-7) to
Ang II
. The results show that
Ang II
decreased transcript expression of
MMP-1
, MMP-2, TIMP-1, TIMP-2 and TIMP-3, but upregulated MMP-9 expression in the HCF cells. Transcript expression of MMP-9 and TIMP-2 was downregulated by Ang(1-7) in the same cells. In the HCM cells,
Ang II
induced
MMP-1
and MMP-9 overexpression but MMP-2 was downregulated. All of the examined MMPs and TIMPs, except MMP-9, were markedly decreased by Ang(1-7). In the studies of antagonistic effects of Ang(1-7) to
Ang II
, Ang(1-7) counteracted the effects of
Ang II
-mediated regulation on MMP-9 and TIMP-1 in the HCF cells compared with the control group. The regulations of all examined MMPs by
Ang II
were reversed to basal expression by Ang(1-7) in the HCM cells. Our results suggest that Ang(1-7) and
Ang II
have opposite and antagonistic effects on regulation of transcription of MMPs and TIMPs in primary cultures of human cardiocytes. These effects lead to increased ratios of MMPs to TIMPs after
Ang II
stimulation and decreased ratios of MMPs to TIMPs after Ang(1-7) stimulation; effects which may partly depend of the type of cardiac cells. These results suggest a potential role for Ang(1-7) in attenuatating cardiac damage in
Ang II
-induced ECM remodelling.
...
PMID:Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes. 1829 91
Clinical evidence links increased aortic collagen content and stiffness to abdominal aortic aneurysm (AAA) formation. However, the possibility that excess collagen contributes to AAA formation remains untested. We investigated the hypothesis that augmented collagen promotes AAA formation, and employed apoE-null mice expressing
collagenase
-resistant mutant collagen (Col(R/R)/apoE(-/-)), heterozygote (Col(R/+)/apoE(-/-)), or wild-type collagen (Col(+/+)/apoE(-/-)) infused with angiotensin II to induce AAA. As expected, the aortas of Col(R/R)/apoE(-/-) mice contained more interstitial collagen than those from the other groups.
Angiotensin II
treatment elicited more AAA formation in Col(R/R)/apoE(-/-) mice than Col(R/+)/apoE(-/-) or Col(+/+)/apoE(-/-) mice. Aortic circumferences correlated positively with collagen content, determined by picrosirius red and Masson trichrome staining. Mechanical testing of aortas of Col(R/R)/apoE(-/-) mice showed increased stiffness and susceptibility to mechanical failure compared to those of Col(+/+)/apoE(-/-) mice. Optical analysis further indicated altered collagen fiber orientation in the adventitia of Col(R/R)/apoE(-/-) mice. These results demonstrate that collagen content regulates aortic biomechanical properties and influences AAA formation.
...
PMID:Genetically engineered resistance for MMP collagenases promotes abdominal aortic aneurysm formation in mice infused with angiotensin II. 1915 55
<< Previous
1
2
3
4
5
Next >>